Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer
Open Access
- 13 September 2005
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 118 (5) , 1279-1284
- https://doi.org/10.1002/ijc.21471
Abstract
Increased levels of insulin‐like growth factor I (IGF‐I) may directly stimulate breast cell proliferation and promote growth and survival of transformed cells. Higher levels of IGF‐I have been associated with increased risk of premenopausal breast cancer but not postmenopausal breast cancer. We investigated whether circulating levels of IGF‐I prior to menopause are associated with breast cancer diagnosed after menopause in a population‐based nested case‐control study. Female cohort participants were enrolled in 1974 (n = 15,192) and 1989 (n = 18,724) and blood was drawn. Cases were women diagnosed with primary breast cancer at ages ≥50, of whom 152 were premenopausal at blood draw. One control was matched to each case on cohort participation, age, ethnic group, menopausal status and date of blood draw. Levels of IGF‐I and IGF binding protein 3 (IGFBP‐3) were measured using enzyme‐linked immunoabsorbant assays assays. The association between IGF‐I and breast cancer was determined using conditional logistic regression, adjusting for IGFBP‐3. IGF‐I levels decreased with age (p = 0.0001). Prior to age‐stratification, IGF‐I levels neither measured before nor after menopause were associated with postmenopausal breast cancer. After age‐stratification, associations were suggested in the youngest premenopausal age group (upper vs. lowest third: odds ratio (OR) = 5.31, 95% confidence intervals (CI) = 0.85–33.13; p trend = 0.06) and oldest postmenopausal age group (upper vs. lowest third: OR = 3.41, 95% CI = 0.66–17.71; p trend = 0.13). The association between circulating levels of IGF‐I and postmenopausal breast cancer risk may be modified by age. Increased levels of circulating IGF‐I may be of particular interest in the younger premenopausal women and older postmenopausal women. Age‐stratification should be undertaken in larger investigations of IGF‐I levels as predictors of postmenopausal breast cancer.Keywords
This publication has 23 references indexed in Scilit:
- Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1Molecular and Cellular Endocrinology, 2005
- Serum concentrations of IGF‐I, IGFBP‐3 and c‐peptide and risk of hyperplasia and cancer of the breast in postmenopausal womenInternational Journal of Cancer, 2003
- Body Mass Index, Serum Sex Hormones, and Breast Cancer Risk in Postmenopausal WomenJNCI Journal of the National Cancer Institute, 2003
- Circulating levels of insulin‐like growth factor I, its binding proteins ‐1,‐2, ‐3, C‐peptide and risk of postmenopausal breast cancerInternational Journal of Cancer, 2003
- The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: Biology and therapeutic relevanceCancer and Metastasis Reviews, 2003
- Serum insulin-like growth factor-I and breast cancerInternational Journal of Cancer, 2000
- Circulating concentrations of insulin-like growth factor I and risk of breast cancerThe Lancet, 1998
- Insulin‐like growth‐factor‐binding protein 3 is decreased in early‐stage operable pre‐menopausal breast cancerInternational Journal of Cancer, 1995
- Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancerEuropean Journal Of Cancer, 1993
- Regression Analysis of Multivariate Incomplete Failure Time Data by Modeling Marginal DistributionsJournal of the American Statistical Association, 1989